|Expense Ratio (net)||0.20%|
|Last Cap Gain||0.00|
|Morningstar Risk Rating||Average|
|Beta (5Y Monthly)||1.00|
|5y Average Return||N/A|
|Average for Category||N/A|
|Inception Date||Nov 08, 2012|
It's nice to see the Humanigen, Inc. ( NASDAQ:HGEN ) share price up 14% in a week. But that doesn't change the fact...
SHORT HILLS, N.J., May 05, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called "cytokine storm" with its lead drug candidate, lenzilumab (LENZ®), today provided a corporate update and reported financial results for the first quarter ended March 31, 2022.
SHORT HILLS, N.J., May 04, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ announced today that management will present and participate at multiple investors conferences in May 2022. Details of the conferences are as follows: